TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24906133
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (1 mg)
Study: 24906133
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (40 mg)
Study: 24906133
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between SBA concentration and propranolol oral AUC0-∞
Study: 22969845
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 + Goshajinkigan treatment (Group B)
Study: 22969845
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 treatment (Group A)
Study: 15742266
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral antibiotic treatment
Study: 15742266
Drug: Postoperative topical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative topical antibiotic drops
Study: 12093661
Drug: Mitomycin-C (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C (0.05 mg/ml) applied topically to the filtering bleb on days 1, 2, and 3 after surgery (postoperative application)
Study: 12093661
Drug: Mitomycin-C (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C (0.2 mg/ml) applied by means of a sponge during surgery (intraoperative application)
Study: 10503682
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (2 mg 8 hourly)
Study: 10503682
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg at entry and again at 24 h)
Study: 8879982
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of standardized ginseng extract Ginsana G 115
Study: 29866165
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula therapy (HFNC)
Study: 27040801
Drug: 13 G
Normalized name: UREA 13 g TOPICAL TABLET [CLEAN-UP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 G vacuum-assisted biopsy (VAB)
Study: 27040801
Drug: 14 G
Normalized name: GINGER 14 g in 100 TOPICAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 G core needle biopsy (CNB)
Study: 22541306
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU-IS)
Study: 22541306
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU-OS)
Study: 20930100
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) consisting of up to ten 1-hour sessions within 6 months
Study: 17684525
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D3 supplement plus 500 mg calcium (CaD group)
Study: 17684525
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 500 mg calcium (Ca group)
Study: 12028741
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg/day)
Study: 1936066
Drug: Eterobarbital (DMMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eterobarbital (DMMP) 400 mg
Study: 1936066
Drug: Phenobarbital (PB)
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (PB) 200 mg
Study: 7022286
Drug: VP-16-213 (etoposide)
Normalized name: etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VP-16-213 (etoposide) administered orally at 150 mg/m2/day for 5 days every 3 weeks
Study: 7022286
Drug: VP-16-213 (etoposide)
Normalized name: etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VP-16-213 (etoposide) administered intravenously at 150 mg/m2 weekly
Study: 30584047
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-testing plus routine door-to-door HIV testing services
Study: 30584047
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-testing plus routine door-to-door HIV testing services (among men)
Study: 26293044
Drug: Tac‐QD (tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tac‐QD (tacrolimus once daily)
Study: 15075539
Drug: 8-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week treatment interruption followed by a six to nine-drug rescue regimen
Study: 15075539
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy alone
Study: 9483586
Drug: Lodoxamide 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide 0.1% ophthalmic solution (LOS)
Study: 7831455
Drug: Haloperidol (neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (neuroleptic treatment)
Study: 3417462
Drug: Intermittent doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent doses of buprenorphine hydrochloride (0.3 mg intramuscularly every 3 to 6 hours)
Study: 25222881
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg and Glycopyrronium 50 μg (combination)
Study: 23886280
Drug: Personal Resilience
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personal Resilience and Enrichment Programme (PREP), six weekly sessions focused on emotional awareness, expression and management, identifying roles and personal strengths, and effective problem-solving skills.
Study: 20332355
Drug: Automated glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Automated glucagon plus insulin delivery
Study: 3931467
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus insulin
Study: 18836798
Drug: Chemoradiotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoradiotherapy followed by chemotherapy
Study: 12716689
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements alone (1000 mg Ca/d)
Study: 11028551
Drug: Perioperative enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative enteral immunonutrition (treatment group, n = 102)
Study: 9160360
Drug: Protamine infusion
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine infusion
Study: 3897895
Drug: Oxiracetam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam (2 X 400 mg capsules t.i.d.)
Study: 28994705
Drug: Purified anthocyanins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified anthocyanins (320 mg/day)
Study: 22889987
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training + whey supplement (RW)
Study: 17442904
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin threshold of 7 g per deciliter)
Study: 17442904
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin threshold of 9.5 g per deciliter)
Study: 16181835
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cisplatin (60 mg/m2 intravenously) and 5-fluorouracil (1,000 mg/m2 per day) for 4 days, three cycles at 3-week intervals
Study: 12909505
Drug: Premarin, 0.625
Normalized name: Premarin, 0.625 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin, 0.625 mg for 25 days monthly, with Provera, 10 mg for 10 of these 25 days (hormone therapy) for 2 years
Study: 9012222
Drug: Golytely solution
DrugBank: Sodium sulfate (DB09472)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Golytely solution (3 litres)
Study: 6349668
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg once daily for 4 weeks
Study: 1974505
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once daily for 4 weeks
Study: 6349668
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg once daily for 4 weeks
Study: 6349668
Drug: Atenolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (all doses)
Study: 30322501
Drug: Early drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early drain removal (drains removed output‐based, i.e., flow less than 30 ml/day)
Study: 22251130
Drug: l-arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (6 g)
Study: 15086925
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g per day
Study: 8110696
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.1 mg
Study: 8110696
Drug: Lingual timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lingual timolol 0.1 mg
Study: 8110696
Drug: Placebo (topical)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (topical)
Study: 9825366
Drug: Antiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic therapy
Study: 2483239
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drugs
Study: 19189
Drug: Adrenergic bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic bronchodilator
Study: 19189
Drug: Post-adrenergic therapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-adrenergic therapy
Study: 31567466
Drug: Standard-dose vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose vaccine
Study: 26406293
Drug: Low AMH
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low AMH (<1.00 ng/mL, n = 124)
Study: 26406293
Drug: Normal AMH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal AMH (1.00-3.5 ng/mL, n = 595)
Study: 26406293
Drug: High AMH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High AMH (>3.5 ng/mL, n = 483)
Study: 23791606
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic cream
Study: 16961168
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (180 - 2160 mg)
Study: 16961168
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (not specified dosage)
Study: 15625835
Drug: Holothuria Ldeucospilota
Normalized name: Holothuria sea cucumber preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holothuria Ldeucospilota Acidic Mucopolysaccharide (HLAM) 60 mg/d
Study: 15625835
Drug: Holothuria Ldeucospilota
Normalized name: Holothuria sea cucumber preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holothuria Ldeucospilota Acidic Mucopolysaccharide (HLAM) 120 mg/d
Study: 23296097
Drug: Tacrolimus modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus modified-release once-daily preparation (Advagraf, Graceptor)
Study: 2942806
Drug: Fenoterol/ipratropium combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol/ipratropium combination (100 micrograms fenoterol and 40 micrograms ipratropium bromide per puff, 2 puffs)
Study: 28007133
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg once daily for 5 years
Study: 25876338
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of acupuncture and tapping method
Study: 3293872
Drug: Tyramine administered
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine administered by bolus injection
Study: 3293872
Drug: Tyramine administered
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine administered by infusion
Study: 23758078
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus weekly/biweekly teleconsultations with an endocrinologist (n=12)
Study: 21478777
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavioral therapy (CBT) plus pedometer-based walking program
Study: 18855558
Drug: Nonadjuvanted RSV
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted RSV vaccine
Study: 18855558
Drug: RSV vaccine
Normalized name: RSV VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV vaccine (both formulations)
Study: 16861098
Drug: Propacetamol 30
Normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 30 mg/kg IV
Study: 12911355
Drug: Oral flexible
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral flexible intubating fibrescope
Study: 8130009
Drug: Low-molecular-heparin (Sandoparin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-heparin (Sandoparin)
Study: 8130009
Drug: Standard-heparin (Liquemin:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-heparin (Liquemin: 3 x 5000 I.E.)
Study: 8130009
Drug: Standard-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-heparin
Study: 8130009
Drug: Low-molecular-heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-heparin
Study: 27249781
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg LSD
Study: 20117912
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.1 mg (group M)
Study: 11149624
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (1.5 mU/kg x min)
Study: 11149624
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (saline solution)
Study: 4048899
Drug: Magaldrate tablets
Normalized name: Magaldrate Tablets
DrugBank: Magaldrate (DB08938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magaldrate tablets
Study: 4048899
Drug: Al-Mg-hydroxide tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Mg-hydroxide tablets
Study: 4048899
Drug: Al-Mg-hydroxide liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Mg-hydroxide liquid
Study: 27063928
Drug: AZP-531 15
Normalized name: Azp-2006 free base
DrugBank: Ezeprogind (DB16954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZP-531 15 µg/kg or higher
Study: 27063928
Drug: AZP-531 60
Normalized name: Azp-2006 free base
DrugBank: Ezeprogind (DB16954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZP-531 60 µg/kg
Study: 24866968
Drug: Dynamic supportive‐expressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic supportive‐expressive therapy
Study: 24866968
Drug: Supportive clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive clinical management combined with pharmacotherapy or placebo
Study: 20822968
Drug: 50 µg/m³
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg/m³ elemental carbon UFP for 2 hr
Study: 17937474
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 to 10 mg/kg) plus methotrexate (MTX)
Study: 7610357
Drug: Pancreatic extract
Normalized name: Pancreatic extract pancrelipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic extract (Pancrex-Duo capsules, 34,375 USP units of protease, 4 capsules four times daily for 4 months)
Study: 7610357
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules four times daily for 4 months)
Study: 2118307
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 320/1,600 mg daily
Study: 2118307
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160/800 mg daily
Study: 215307
Drug: Thymosin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin at a dose of 60 mg/m2
Study: 215307
Drug: Thymosin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin at a dose of 20 mg/m2
Study: 28618724
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg/BD/IM)
Study: 23588235
Drug: Lactulose 25
Normalized name: lactulose 2500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose 25 g
Study: 19513632
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (o.d.) dosing of insulin detemir
Study: 19513632
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (b.i.d.) dosing of insulin detemir
Study: 19513632
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from o.d. to b.i.d. dosing
Study: 16426286
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream containing vaseline
Study: 16426286
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream containing bees wax
Study: 16426286
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream containing waxes and surfactant
Study: 16426286
Drug: No barrier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: No barrier cream (control)
Study: 12877903
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/day for 4 weeks
Study: 8818851
Drug: Co-amoxiclav (37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (37 mg three times daily for 10 days)
Study: 28750695
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg twice daily + low-dose aspirin (ASA)
Study: 28750695
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg twice daily + low-dose ASA
Study: 28750695
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + low-dose aspirin (ASA)
Study: 19406232
Drug: Lyophilized orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized orally disintegrating tablets (ODTs) of nimesulide (100mg)
Study: 19406232
Drug: Conventional immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immediate release tablet (Sulide)
Study: 11134193
Drug: Doxorubicin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (n = 637, median total dose of 294 mg/m(2))
Study: 7956752
Drug: Resumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resumption of treatment during follow-up
Study: 2837046
Drug: Indomethacin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 1% ophthalmic solution (one drop the evening before surgery and one drop 45 minutes before surgery)
Study: 27733560
Drug: Inhaled CVT‐301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled CVT‐301 (50 mg)
Study: 27733560
Drug: Oral carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbidopa/levodopa (25 mg/100 mg)
Study: 23347336
Drug: Preoperatively 2
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperatively 2 g of amoxycillin 1 h before surgery (positive control, PC)
Study: 23347336
Drug: Postoperatively 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperatively 2 g of amoxycillin immediately following surgery (test 1, T1)
Study: 23347336
Drug: Preoperatively 2
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperatively 2 g of amoxycillin 1 h before and 500 mg thrice daily on days 2 and 3 after surgery (test 2, T2)
Study: 23347336
Drug: Preoperatively 2
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperatively 2 g of placebo 1 h before surgery (negative control, NC)
Study: 18299694
Drug: General measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: General measurements (low dose and short period of glucocorticoids)
Study: 16805710
Drug: Platinum-based adjuvant
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC
Study: 16805710
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy in resected stage III NSCLC
Study: 11061252
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (low-dose lorazepam)
Study: 3615347
Drug: Clovoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clovoxamine 50 mg, 100 mg, 150 mg
Study: 7341285
Drug: Mianserin 20
Normalized name: mianserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 20 mg
Study: 26724489
Drug: Elevated baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated baseline BNP (> median = 72 ng/L)
Study: 31425658
Drug: Tinnitus Retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus Retraining Therapy (TRT)
Study: 25319676
Drug: TRT counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT counseling and sound therapy
Study: 15358440
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH, Somatropin) replacement therapy for 6 months (Group I)